Watson Pharmaceuticals a leading pharmaceutical announced that USFDA has approved Rapaflo (silodosin) the companys new alpha blocker for the treatment of the signs and symptoms of benign prostatic Hyperplasia (BPH).Rapaflo is an effective selective alpha-1 adrenergic receptor antagonist.The most common side effect with Rapaflo is reduced or no semen during orgasm, dizziness, light headedness, diarrhea, orthostatic hypotension, headache, nasopharyngitis and nasal congestion. Patients on alpha blockers or those who have severe kidney or liver impairment should not use Rapaflo.

Reference-www.fda.gov